10th PAGE Meeting

  • Basel - Switzerland
  • 7 - 8 June, 2001
View abstracts
Home / 2001 – Basel – Switzerland / Program
Thursday June 7
08:00-08:45 Registration and coffee
08:40-09:00 Welcome and Introduction
James Shannon, Director of Clinical Research and Development, Novartis
Oral session I Physiologically-Based Pharmacokinetics chair: Amy Racine / Mick Looby
09:00-09:30 Ryosei Leo Kawai Impact of PK variables assessed by physiologically-based PK models
09:30-10:00 Ivan Nestorov Sensitivity analysis of PBPK and PK/PD models
10:00-10:20 Fredrik Jonsson Contributed paper (1): Physiologically based pharmacokinetic modeling in risk assessment - Development of Bayesian population methods
10:20-12:10 Coffee Poster and Software session I
Posters with even numbers are accompanied by their presenter
Tutorial chair: Amy Racine / Mick Looby
12:10-12:50 Joe Schafer Multiple Imputation for Missing data problems
12:50-14:20 Lunch
Oral session II Disease progression modelling chair: Oscar della Pasqua
14:20-15:00 Paolo Vicini Integrated system models to understand disease status, progression and therapy: case studies
15:00-15:20 Julie Simpson The natural progression of P.falciparum malaria: Investigation of a historical cohort of syphilis patients treated with malariatherapy
15:20-15:40 Mats Karlsson Models for sedation scores in acute stroke patients
15:40-16:00 Nick Holford Auckland bones and summer sun.
16:00-16:20 Tea and Software
Oral session III Contributed papers chair: Peter Milligan
16:20-16:40 Philip Jacqmin Contributed paper (2): Modeling drug induced changes in biomarkers without using drug concentrations: Introducing the K-PD model
16:40-17:00 Timothy Goggin Contributed paper (3): Population PD(-PK) modeling and clinical trial simulation, characterizing schedule dependence of hematotoxicity and other Phase II trial design features for a new oral anticancer drug
17:00-18:00 Planning of future PAGE meetings & organization
Coordinated by Mats Karlsson, Pascal Girard, Jakob Schenker, Jean-Louis Steimer
For all those interested
19:00-24:00 Social Evening
at Safranzunft, Gerbergasse (close to Marktplatz), Basel
Friday June 8
Oral session IV Contributed papers chair: France Mentre
09:00-09:20 Lewis Sheiner Contributed paper (4): Dealing with Missing Data in Longitudinal Studies through Modeling
09:20-09:40 Gordon Graham Contributed paper (5): Bayesian Optimal Design Applied to Mixed Effect Pharmacokinetic Models
09:40-10:00 James Wright Contributed paper (6): Forward selection and other recipes for disaster
10:00-11:50 Coffee Poster and Software session II
Posters with uneven/odd numbers are accompanied by their presenter
Oral session V Contributed papers chair: Janet Wade
11:50-12:10 Hui Kimko Contributed paper (7): Iron kinetics: when drug loss by sampling is critical in data analysis
12:10-12:30 Philip Lowe Contributed paper (8): On mechanism based PK/PD modelling for direct drug-ligand binding systems
12:30-12:50 Leon Aarons Contributed paper (9): The role of modelling and simulation in the clinical development of anti-cancer agents
12:50-14:20 Lunch
Oral session VI Endogenous products/biotech products chair: Rik Schoemaker
14:20-14:40 Niclas Jonsson A mechanism based population PK/PD model of UK-279,276 in healthy volunteers and patients
14:40-15:00 Per-Henrik Zingmark Dose-Concentration-FACS models for the monoclonal antibody ATM-027, developed for the treatment of Multiple Sclerosis
15:00-15:20 Christian Laveille Hormone exposure and effects on Follicle-Stimulating Hormone (FSH) after nasal administration of estradiol in postmenopausal women
Oral session VII How to manage data around LOQ chair: Leon Aarons
15:40-16:00 Dave Lunn Graphical models and missing data
16:00-16:20 Vincent Duval Contributed paper (10): Influence of LOQ on the PK parameters after an IV bolus dose
16:20-16:40 Ferdie Rombout LOQ, a relic of the past?
16:40-17:00 Concluding remarks/preview PAGE 2002, Paris